English

    Overview

  • Dr. Peush Bajpai is a respected HOD and Consultant Medical Hemato-Oncologist at Manipal Hospitals, Delhi. With over 17 years of experience in the field, Dr. Bajpai has dedicated his career to the comprehensive treatment of various cancers, earning him a distinguished reputation among both patients and peers.

  • Moreover, Dr. Bajpai is equally well-versed with solid cancers like breast, lung, gastrointestinal, stomach, prostate, head, and neck as well as hematologic malignancies. Through his extensive experience, he is capable of offering individual and advanced cancer treatment according to each patient's needs.

  • Educationally, Dr. Bajpai completed his MBBS and MD in General Medicine before specialising with a DM in Medical Oncology from the Cancer Institute, Adyar, Chennai. He is also accredited by the European Society of Medical Oncology (ESMO), which underscores his commitment to maintaining the highest standards in oncology practice. His academic credentials are complemented by his participation in numerous research projects and clinical trials, which contribute to the advancement of cancer treatment and patient care.

  • Dr. Bajpai is actively involved in the broader medical community through his membership in several prestigious associations, including the Indian Medical Association (IMA), the Association of Physicians of India (API), and the Indian Society of Medical Oncology (ISMO). His involvement in these organizations reflects his dedication to staying at the forefront of medical advancements and best practices.

  • In addition to his clinical and academic work, Dr. Bajpai has contributed significantly to medical literature through numerous publications and presentations at national and international conferences. His research covers a wide range of topics within oncology, providing valuable insights and advancements that benefit both his patients and the broader medical community.

  • At Manipal Hospitals, Delhi, Dr. Bajpai, one of the best Oncologists in Delhi, leads a team of skilled professionals dedicated to delivering comprehensive and cutting-edge cancer care. His leadership and expertise ensure that patients receive the most effective treatments available, backed by the latest research and clinical guidelines.

  • Dr. Bajpai’s unwavering commitment as an Oncologist in Delhi, combined with his extensive experience and advanced skills, make him a trusted and valued figure in the field of oncology in Delhi. For patients seeking expert and compassionate cancer care, Dr. Peush Bajpai represents the epitome of professional excellence. Book your appointment today for optimum care and patient-centric support.

  • Field of Expertise

  • Breast Cancer Management Gastrointestinal malignancies- Gastric, colo-rectal, hepatocellular carcinoma
  • Gynaecological Malignancies - Carcinoma Ovary, the endometrium
  • Haematological Malignancies - Multiple Myeloma, CML, CLL, and Autologous Bone marrow transplant
  • Soft-tissue Sarcomas and Osteosarcoma
  • Thoracic Malignancies - Lung Carcinoma
  • Immunotherapy
  • Precision Oncology
  • Fellowship & Membership

  • European Society of Medical Oncology (ESMO)
  • ASCO
  • NCR oncology group
  • ISMPO
  • ICON
  • Dwarka IMA
  • SIOP
  • Languages Spoken

  • English
  • Hindi
  • Tamil
  • Awards & Achievements

  • First prize as a part of a team in a Case presentation at the UK Breast Oncoplasty Masterclass.
  • First prize in the All India Quiz at the Lymphoma leukemia meet in Mumbai organized by the European Society of Medical Oncology.
  • Best poster in BTG Hong Kong โ€Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.
  • Talks & Publications

  • Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
  • Kandakumar V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one year oldchild Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
  • Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
  • Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2.Peush Bajpai et al.
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages943–946 (2019).
  • Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
  • Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
  • Bajpai, P. et al Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
  • Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. Asia-Pacific Hematology consortium held during 22- 23 Feb 2013 at Hongkong BTG2013 Abstract (20):20-21.
  • A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
  • A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
  • A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
  • Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk assessment Scale for high age patient).
  • Have Organized SABCS( San Antonio Breast Cancer update 2016 under the aegis of Delhi Breast Oncology Group.
  • Delhi Breast Oncology group meeting @ Manipal Hospital Dwarka in August 2018.
  • Co-Organizer of Best Of SABCS 2018 April 2018.
  • Organized workshop at Manipal Hospital Dwarka on Good Clinical Practice (GCP) on 1st March 2019.
  • CME on prostate cancer – CONFLUENCE meeting on Prostate Cancer -12 October 2019.
  • Dr. Peush Bajpai in an authored article on know the warning signs when to approach your doctor observing the Breast cancer Awareness month in the DNA. Click Here
  • Dr. Peush Bajpai explains about how early diagnosis and detection can identify Breast Cancer symptoms and treat it successfully on TV9 Bharatvarsh (Digital) | FB Live Session. Click Here
  • Dr. Peush Bajpai in an authored article on Watch out, lumps are not the only symptom of breast cancer observing Breast Cancer Awareness Month in Times Now News. Click Here
  • Dr. Peush Bajpai in an exclusive story on Oncologist answers FAQs on the ideal routine for cancer treatment in Times Now| World Cancer Day. Click Here
  • Dr. Peush Bajpai on Cancer and Precision Medicine in a live webinar on Business World.Click Here
  • Dr. Peush Bajpai on Cancer Treatment: Can I Have Chemotherapy During Pregnancy? in The Healthsite (Zee Digital) | Exclusive story.Click Here
  • Dr. Peush Bajpai on Doctor Explains: Menace of cancer in India| The Financial Express | World Cancer Day. Click Here
  • Dr. Peush Bajpai said in an exclusive Story, "Nearly 50-60 per cent cancers are due to poor lifestyle" to Financial Express. Click Here
  • SM Post | NDTV. Click Here

    Fellowship & Membership

  • European Society of Medical Oncology (ESMO)
  • ASCO
  • NCR oncology group
  • ISMPO
  • ICON
  • Dwarka IMA
  • SIOP
  • Overview

  • Dr. Peush Bajpai is a respected HOD and Consultant Medical Hemato-Oncologist at Manipal Hospitals, Delhi. With over 17 years of experience in the field, Dr. Bajpai has dedicated his career to the comprehensive treatment of various cancers, earning him a distinguished reputation among both patients and peers.

  • Moreover, Dr. Bajpai is equally well-versed with solid cancers like breast, lung, gastrointestinal, stomach, prostate, head, and neck as well as hematologic malignancies. Through his extensive experience, he is capable of offering individual and advanced cancer treatment according to each patient's needs.

  • Educationally, Dr. Bajpai completed his MBBS and MD in General Medicine before specialising with a DM in Medical Oncology from the Cancer Institute, Adyar, Chennai. He is also accredited by the European Society of Medical Oncology (ESMO), which underscores his commitment to maintaining the highest standards in oncology practice. His academic credentials are complemented by his participation in numerous research projects and clinical trials, which contribute to the advancement of cancer treatment and patient care.

  • Dr. Bajpai is actively involved in the broader medical community through his membership in several prestigious associations, including the Indian Medical Association (IMA), the Association of Physicians of India (API), and the Indian Society of Medical Oncology (ISMO). His involvement in these organizations reflects his dedication to staying at the forefront of medical advancements and best practices.

  • In addition to his clinical and academic work, Dr. Bajpai has contributed significantly to medical literature through numerous publications and presentations at national and international conferences. His research covers a wide range of topics within oncology, providing valuable insights and advancements that benefit both his patients and the broader medical community.

  • At Manipal Hospitals, Delhi, Dr. Bajpai, one of the best Oncologists in Delhi, leads a team of skilled professionals dedicated to delivering comprehensive and cutting-edge cancer care. His leadership and expertise ensure that patients receive the most effective treatments available, backed by the latest research and clinical guidelines.

  • Dr. Bajpai’s unwavering commitment as an Oncologist in Delhi, combined with his extensive experience and advanced skills, make him a trusted and valued figure in the field of oncology in Delhi. For patients seeking expert and compassionate cancer care, Dr. Peush Bajpai represents the epitome of professional excellence. Book your appointment today for optimum care and patient-centric support.

  • Field of Expertise

  • Breast Cancer Management Gastrointestinal malignancies- Gastric, colo-rectal, hepatocellular carcinoma
  • Gynaecological Malignancies - Carcinoma Ovary, the endometrium
  • Haematological Malignancies - Multiple Myeloma, CML, CLL, and Autologous Bone marrow transplant
  • Soft-tissue Sarcomas and Osteosarcoma
  • Thoracic Malignancies - Lung Carcinoma
  • Immunotherapy
  • Precision Oncology
  • Languages Spoken

  • English
  • Hindi
  • Tamil
  • Awards & Achievements

  • First prize as a part of a team in a Case presentation at the UK Breast Oncoplasty Masterclass.
  • First prize in the All India Quiz at the Lymphoma leukemia meet in Mumbai organized by the European Society of Medical Oncology.
  • Best poster in BTG Hong Kong โ€Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.
  • Talks & Publications

  • Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
  • Kandakumar V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one year oldchild Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
  • Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
  • Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2.Peush Bajpai et al.
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages943–946 (2019).
  • Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
  • Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
  • Bajpai, P. et al Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
  • Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. Asia-Pacific Hematology consortium held during 22- 23 Feb 2013 at Hongkong BTG2013 Abstract (20):20-21.
  • A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
  • A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
  • A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
  • Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk assessment Scale for high age patient).
  • Have Organized SABCS( San Antonio Breast Cancer update 2016 under the aegis of Delhi Breast Oncology Group.
  • Delhi Breast Oncology group meeting @ Manipal Hospital Dwarka in August 2018.
  • Co-Organizer of Best Of SABCS 2018 April 2018.
  • Organized workshop at Manipal Hospital Dwarka on Good Clinical Practice (GCP) on 1st March 2019.
  • CME on prostate cancer – CONFLUENCE meeting on Prostate Cancer -12 October 2019.
  • Dr. Peush Bajpai in an authored article on know the warning signs when to approach your doctor observing the Breast cancer Awareness month in the DNA. Click Here
  • Dr. Peush Bajpai explains about how early diagnosis and detection can identify Breast Cancer symptoms and treat it successfully on TV9 Bharatvarsh (Digital) | FB Live Session. Click Here
  • Dr. Peush Bajpai in an authored article on Watch out, lumps are not the only symptom of breast cancer observing Breast Cancer Awareness Month in Times Now News. Click Here
  • Dr. Peush Bajpai in an exclusive story on Oncologist answers FAQs on the ideal routine for cancer treatment in Times Now| World Cancer Day. Click Here
  • Dr. Peush Bajpai on Cancer and Precision Medicine in a live webinar on Business World.Click Here
  • Dr. Peush Bajpai on Cancer Treatment: Can I Have Chemotherapy During Pregnancy? in The Healthsite (Zee Digital) | Exclusive story.Click Here
  • Dr. Peush Bajpai on Doctor Explains: Menace of cancer in India| The Financial Express | World Cancer Day. Click Here
  • Dr. Peush Bajpai said in an exclusive Story, "Nearly 50-60 per cent cancers are due to poor lifestyle" to Financial Express. Click Here
  • SM Post | NDTV. Click Here

    Languages Spoken

  • English
  • Hindi
  • Tamil
  • Overview

  • Dr. Peush Bajpai is a respected HOD and Consultant Medical Hemato-Oncologist at Manipal Hospitals, Delhi. With over 17 years of experience in the field, Dr. Bajpai has dedicated his career to the comprehensive treatment of various cancers, earning him a distinguished reputation among both patients and peers.

  • Moreover, Dr. Bajpai is equally well-versed with solid cancers like breast, lung, gastrointestinal, stomach, prostate, head, and neck as well as hematologic malignancies. Through his extensive experience, he is capable of offering individual and advanced cancer treatment according to each patient's needs.

  • Educationally, Dr. Bajpai completed his MBBS and MD in General Medicine before specialising with a DM in Medical Oncology from the Cancer Institute, Adyar, Chennai. He is also accredited by the European Society of Medical Oncology (ESMO), which underscores his commitment to maintaining the highest standards in oncology practice. His academic credentials are complemented by his participation in numerous research projects and clinical trials, which contribute to the advancement of cancer treatment and patient care.

  • Dr. Bajpai is actively involved in the broader medical community through his membership in several prestigious associations, including the Indian Medical Association (IMA), the Association of Physicians of India (API), and the Indian Society of Medical Oncology (ISMO). His involvement in these organizations reflects his dedication to staying at the forefront of medical advancements and best practices.

  • In addition to his clinical and academic work, Dr. Bajpai has contributed significantly to medical literature through numerous publications and presentations at national and international conferences. His research covers a wide range of topics within oncology, providing valuable insights and advancements that benefit both his patients and the broader medical community.

  • At Manipal Hospitals, Delhi, Dr. Bajpai, one of the best Oncologists in Delhi, leads a team of skilled professionals dedicated to delivering comprehensive and cutting-edge cancer care. His leadership and expertise ensure that patients receive the most effective treatments available, backed by the latest research and clinical guidelines.

  • Dr. Bajpai’s unwavering commitment as an Oncologist in Delhi, combined with his extensive experience and advanced skills, make him a trusted and valued figure in the field of oncology in Delhi. For patients seeking expert and compassionate cancer care, Dr. Peush Bajpai represents the epitome of professional excellence. Book your appointment today for optimum care and patient-centric support.

  • Fellowship & Membership

  • European Society of Medical Oncology (ESMO)
  • ASCO
  • NCR oncology group
  • ISMPO
  • ICON
  • Dwarka IMA
  • SIOP
  • Field of Expertise

  • Breast Cancer Management Gastrointestinal malignancies- Gastric, colo-rectal, hepatocellular carcinoma
  • Gynaecological Malignancies - Carcinoma Ovary, the endometrium
  • Haematological Malignancies - Multiple Myeloma, CML, CLL, and Autologous Bone marrow transplant
  • Soft-tissue Sarcomas and Osteosarcoma
  • Thoracic Malignancies - Lung Carcinoma
  • Immunotherapy
  • Precision Oncology
  • Awards & Achievements

  • First prize as a part of a team in a Case presentation at the UK Breast Oncoplasty Masterclass.
  • First prize in the All India Quiz at the Lymphoma leukemia meet in Mumbai organized by the European Society of Medical Oncology.
  • Best poster in BTG Hong Kong โ€Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.
  • Talks & Publications

  • Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
  • Kandakumar V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one year oldchild Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
  • Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
  • Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2.Peush Bajpai et al.
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages943–946 (2019).
  • Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
  • Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
  • Bajpai, P. et al Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
  • Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. Asia-Pacific Hematology consortium held during 22- 23 Feb 2013 at Hongkong BTG2013 Abstract (20):20-21.
  • A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
  • A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
  • A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
  • Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk assessment Scale for high age patient).
  • Have Organized SABCS( San Antonio Breast Cancer update 2016 under the aegis of Delhi Breast Oncology Group.
  • Delhi Breast Oncology group meeting @ Manipal Hospital Dwarka in August 2018.
  • Co-Organizer of Best Of SABCS 2018 April 2018.
  • Organized workshop at Manipal Hospital Dwarka on Good Clinical Practice (GCP) on 1st March 2019.
  • CME on prostate cancer – CONFLUENCE meeting on Prostate Cancer -12 October 2019.
  • Dr. Peush Bajpai in an authored article on know the warning signs when to approach your doctor observing the Breast cancer Awareness month in the DNA. Click Here
  • Dr. Peush Bajpai explains about how early diagnosis and detection can identify Breast Cancer symptoms and treat it successfully on TV9 Bharatvarsh (Digital) | FB Live Session. Click Here
  • Dr. Peush Bajpai in an authored article on Watch out, lumps are not the only symptom of breast cancer observing Breast Cancer Awareness Month in Times Now News. Click Here
  • Dr. Peush Bajpai in an exclusive story on Oncologist answers FAQs on the ideal routine for cancer treatment in Times Now| World Cancer Day. Click Here
  • Dr. Peush Bajpai on Cancer and Precision Medicine in a live webinar on Business World.Click Here
  • Dr. Peush Bajpai on Cancer Treatment: Can I Have Chemotherapy During Pregnancy? in The Healthsite (Zee Digital) | Exclusive story.Click Here
  • Dr. Peush Bajpai on Doctor Explains: Menace of cancer in India| The Financial Express | World Cancer Day. Click Here
  • Dr. Peush Bajpai said in an exclusive Story, "Nearly 50-60 per cent cancers are due to poor lifestyle" to Financial Express. Click Here
  • SM Post | NDTV. Click Here

    Field of Expertise

  • Breast Cancer Management Gastrointestinal malignancies- Gastric, colo-rectal, hepatocellular carcinoma
  • Gynaecological Malignancies - Carcinoma Ovary, the endometrium
  • Haematological Malignancies - Multiple Myeloma, CML, CLL, and Autologous Bone marrow transplant
  • Soft-tissue Sarcomas and Osteosarcoma
  • Thoracic Malignancies - Lung Carcinoma
  • Immunotherapy
  • Precision Oncology
  • Fellowship & Membership

  • European Society of Medical Oncology (ESMO)
  • ASCO
  • NCR oncology group
  • ISMPO
  • ICON
  • Dwarka IMA
  • SIOP
  • Languages Spoken

  • English
  • Hindi
  • Tamil
  • Awards & Achievements

  • First prize as a part of a team in a Case presentation at the UK Breast Oncoplasty Masterclass.
  • First prize in the All India Quiz at the Lymphoma leukemia meet in Mumbai organized by the European Society of Medical Oncology.
  • Best poster in BTG Hong Kong โ€Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.
  • Talks & Publications

  • Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
  • Kandakumar V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one year oldchild Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
  • Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
  • Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2.Peush Bajpai et al.
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages943–946 (2019).
  • Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
  • Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
  • Bajpai, P. et al Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
  • Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. Asia-Pacific Hematology consortium held during 22- 23 Feb 2013 at Hongkong BTG2013 Abstract (20):20-21.
  • A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
  • A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
  • A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
  • Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk assessment Scale for high age patient).
  • Have Organized SABCS( San Antonio Breast Cancer update 2016 under the aegis of Delhi Breast Oncology Group.
  • Delhi Breast Oncology group meeting @ Manipal Hospital Dwarka in August 2018.
  • Co-Organizer of Best Of SABCS 2018 April 2018.
  • Organized workshop at Manipal Hospital Dwarka on Good Clinical Practice (GCP) on 1st March 2019.
  • CME on prostate cancer – CONFLUENCE meeting on Prostate Cancer -12 October 2019.
  • Dr. Peush Bajpai in an authored article on know the warning signs when to approach your doctor observing the Breast cancer Awareness month in the DNA. Click Here
  • Dr. Peush Bajpai explains about how early diagnosis and detection can identify Breast Cancer symptoms and treat it successfully on TV9 Bharatvarsh (Digital) | FB Live Session. Click Here
  • Dr. Peush Bajpai in an authored article on Watch out, lumps are not the only symptom of breast cancer observing Breast Cancer Awareness Month in Times Now News. Click Here
  • Dr. Peush Bajpai in an exclusive story on Oncologist answers FAQs on the ideal routine for cancer treatment in Times Now| World Cancer Day. Click Here
  • Dr. Peush Bajpai on Cancer and Precision Medicine in a live webinar on Business World.Click Here
  • Dr. Peush Bajpai on Cancer Treatment: Can I Have Chemotherapy During Pregnancy? in The Healthsite (Zee Digital) | Exclusive story.Click Here
  • Dr. Peush Bajpai on Doctor Explains: Menace of cancer in India| The Financial Express | World Cancer Day. Click Here
  • Dr. Peush Bajpai said in an exclusive Story, "Nearly 50-60 per cent cancers are due to poor lifestyle" to Financial Express. Click Here
  • SM Post | NDTV. Click Here
  • Overview

  • Dr. Peush Bajpai is a respected HOD and Consultant Medical Hemato-Oncologist at Manipal Hospitals, Delhi. With over 17 years of experience in the field, Dr. Bajpai has dedicated his career to the comprehensive treatment of various cancers, earning him a distinguished reputation among both patients and peers.

  • Moreover, Dr. Bajpai is equally well-versed with solid cancers like breast, lung, gastrointestinal, stomach, prostate, head, and neck as well as hematologic malignancies. Through his extensive experience, he is capable of offering individual and advanced cancer treatment according to each patient's needs.

  • Educationally, Dr. Bajpai completed his MBBS and MD in General Medicine before specialising with a DM in Medical Oncology from the Cancer Institute, Adyar, Chennai. He is also accredited by the European Society of Medical Oncology (ESMO), which underscores his commitment to maintaining the highest standards in oncology practice. His academic credentials are complemented by his participation in numerous research projects and clinical trials, which contribute to the advancement of cancer treatment and patient care.

  • Dr. Bajpai is actively involved in the broader medical community through his membership in several prestigious associations, including the Indian Medical Association (IMA), the Association of Physicians of India (API), and the Indian Society of Medical Oncology (ISMO). His involvement in these organizations reflects his dedication to staying at the forefront of medical advancements and best practices.

  • In addition to his clinical and academic work, Dr. Bajpai has contributed significantly to medical literature through numerous publications and presentations at national and international conferences. His research covers a wide range of topics within oncology, providing valuable insights and advancements that benefit both his patients and the broader medical community.

  • At Manipal Hospitals, Delhi, Dr. Bajpai, one of the best Oncologists in Delhi, leads a team of skilled professionals dedicated to delivering comprehensive and cutting-edge cancer care. His leadership and expertise ensure that patients receive the most effective treatments available, backed by the latest research and clinical guidelines.

  • Dr. Bajpai’s unwavering commitment as an Oncologist in Delhi, combined with his extensive experience and advanced skills, make him a trusted and valued figure in the field of oncology in Delhi. For patients seeking expert and compassionate cancer care, Dr. Peush Bajpai represents the epitome of professional excellence. Book your appointment today for optimum care and patient-centric support.

    Awards & Achievements

  • First prize as a part of a team in a Case presentation at the UK Breast Oncoplasty Masterclass.
  • First prize in the All India Quiz at the Lymphoma leukemia meet in Mumbai organized by the European Society of Medical Oncology.
  • Best poster in BTG Hong Kong โ€Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.
  • Fellowship & Membership

  • European Society of Medical Oncology (ESMO)
  • ASCO
  • NCR oncology group
  • ISMPO
  • ICON
  • Dwarka IMA
  • SIOP
  • Field of Expertise

  • Breast Cancer Management Gastrointestinal malignancies- Gastric, colo-rectal, hepatocellular carcinoma
  • Gynaecological Malignancies - Carcinoma Ovary, the endometrium
  • Haematological Malignancies - Multiple Myeloma, CML, CLL, and Autologous Bone marrow transplant
  • Soft-tissue Sarcomas and Osteosarcoma
  • Thoracic Malignancies - Lung Carcinoma
  • Immunotherapy
  • Precision Oncology
  • Languages Spoken

  • English
  • Hindi
  • Tamil
  • Talks & Publications

  • Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
  • Kandakumar V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one year oldchild Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
  • Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
  • Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2.Peush Bajpai et al.
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages943–946 (2019).
  • Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
  • Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
  • Bajpai, P. et al Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
  • Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. Asia-Pacific Hematology consortium held during 22- 23 Feb 2013 at Hongkong BTG2013 Abstract (20):20-21.
  • A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
  • A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
  • A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
  • Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk assessment Scale for high age patient).
  • Have Organized SABCS( San Antonio Breast Cancer update 2016 under the aegis of Delhi Breast Oncology Group.
  • Delhi Breast Oncology group meeting @ Manipal Hospital Dwarka in August 2018.
  • Co-Organizer of Best Of SABCS 2018 April 2018.
  • Organized workshop at Manipal Hospital Dwarka on Good Clinical Practice (GCP) on 1st March 2019.
  • CME on prostate cancer – CONFLUENCE meeting on Prostate Cancer -12 October 2019.
  • Dr. Peush Bajpai in an authored article on know the warning signs when to approach your doctor observing the Breast cancer Awareness month in the DNA. Click Here
  • Dr. Peush Bajpai explains about how early diagnosis and detection can identify Breast Cancer symptoms and treat it successfully on TV9 Bharatvarsh (Digital) | FB Live Session. Click Here
  • Dr. Peush Bajpai in an authored article on Watch out, lumps are not the only symptom of breast cancer observing Breast Cancer Awareness Month in Times Now News. Click Here
  • Dr. Peush Bajpai in an exclusive story on Oncologist answers FAQs on the ideal routine for cancer treatment in Times Now| World Cancer Day. Click Here
  • Dr. Peush Bajpai on Cancer and Precision Medicine in a live webinar on Business World.Click Here
  • Dr. Peush Bajpai on Cancer Treatment: Can I Have Chemotherapy During Pregnancy? in The Healthsite (Zee Digital) | Exclusive story.Click Here
  • Dr. Peush Bajpai on Doctor Explains: Menace of cancer in India| The Financial Express | World Cancer Day. Click Here
  • Dr. Peush Bajpai said in an exclusive Story, "Nearly 50-60 per cent cancers are due to poor lifestyle" to Financial Express. Click Here
  • SM Post | NDTV. Click Here
  • Overview

  • Dr. Peush Bajpai is a respected HOD and Consultant Medical Hemato-Oncologist at Manipal Hospitals, Delhi. With over 17 years of experience in the field, Dr. Bajpai has dedicated his career to the comprehensive treatment of various cancers, earning him a distinguished reputation among both patients and peers.

  • Moreover, Dr. Bajpai is equally well-versed with solid cancers like breast, lung, gastrointestinal, stomach, prostate, head, and neck as well as hematologic malignancies. Through his extensive experience, he is capable of offering individual and advanced cancer treatment according to each patient's needs.

  • Educationally, Dr. Bajpai completed his MBBS and MD in General Medicine before specialising with a DM in Medical Oncology from the Cancer Institute, Adyar, Chennai. He is also accredited by the European Society of Medical Oncology (ESMO), which underscores his commitment to maintaining the highest standards in oncology practice. His academic credentials are complemented by his participation in numerous research projects and clinical trials, which contribute to the advancement of cancer treatment and patient care.

  • Dr. Bajpai is actively involved in the broader medical community through his membership in several prestigious associations, including the Indian Medical Association (IMA), the Association of Physicians of India (API), and the Indian Society of Medical Oncology (ISMO). His involvement in these organizations reflects his dedication to staying at the forefront of medical advancements and best practices.

  • In addition to his clinical and academic work, Dr. Bajpai has contributed significantly to medical literature through numerous publications and presentations at national and international conferences. His research covers a wide range of topics within oncology, providing valuable insights and advancements that benefit both his patients and the broader medical community.

  • At Manipal Hospitals, Delhi, Dr. Bajpai, one of the best Oncologists in Delhi, leads a team of skilled professionals dedicated to delivering comprehensive and cutting-edge cancer care. His leadership and expertise ensure that patients receive the most effective treatments available, backed by the latest research and clinical guidelines.

  • Dr. Bajpai’s unwavering commitment as an Oncologist in Delhi, combined with his extensive experience and advanced skills, make him a trusted and valued figure in the field of oncology in Delhi. For patients seeking expert and compassionate cancer care, Dr. Peush Bajpai represents the epitome of professional excellence. Book your appointment today for optimum care and patient-centric support.

    Talks & Publications

  • Bajpai P, Ganesan P. Rajendranath, R. and Sagar TG (2012) CaseReport – “ Rare case of hairy cell leukemia in a patient of head and neck malignancy http://medej.tnmgrmu.ac.in 2 (2).
  • Kandakumar V, Ganesan P, Bajpai P (2011) A rare case of peripheral T-cell lymphoma in one year oldchild Indian J Med Paediatr Oncol. 2011 Oct-Dec; 32(4): 227–229.
  • Methotrexate Induced Acute Encephalopathy-Occurrence on Re-challenge and Response to Aminophylline. Indian J Hematol Blood Transfus 2014 Sep 12;30(Suppl 1):105-7. Epub 2013 Jun 12. Peush Bajpai et al.
  • Novel formulations of docetaxel, paclitaxel, and doxorubicin in the management of metastatic breast cancer Oncol Lett 2018 Sep 2;16(3):3757-3769. Epub 2018 Jul 2.Peush Bajpai et al.
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce a Durable Response Peush Bajpai et al. Journal of Gastrointestinal Cancer volume 50, pages943–946 (2019).
  • Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy South Asian J Cancer. 2019 Jan-Mar; 8(1): 65–68. Peush Bajpai et al.
  • Submitted for Publication: Collusion: The façade and its implications on Total pain management in palliative care -IJPC_81_20 (Indian Journal of palliative care Bajpai, P entitled “Retrospective analysis of adolescent ALL outcomes on BFM 86 protocol in “Lymphoma & Leukemia “(2012) international conference organized by ICONESCON held at Mumbai.
  • Bajpai, P. et al Poster presentation: Cardiac Status in Long Term Survivors after Anthracycline Therapy in Lymphoma a prospective study of 141 patients, ICON 2009 Chennai.
  • Prospective evaluation of musculoskeletal events in patients of Chronic Myeloid Leukemia – Chronic Phase treated with Imatinib mesylate AND possible correlation with electrolyte imbalances. Asia-Pacific Hematology consortium held during 22- 23 Feb 2013 at Hongkong BTG2013 Abstract (20):20-21.
  • A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.
  • A multi-center, observational, data collection registry study to monitor the routine clinical use of MABTAS (RITUXIMAB 100 MG / 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION, MANUFACTURED BY INTAS PHARMACEUTICALS LTD) in Indian patients.
  • A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a Firstline Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma.
  • Coguide for Thesis Diplomate National Board (DNB) Medical Assessment of Toxicity of Chemotherapy in Indian Geriatric patient population and Utility Of CRASH-(Chemotherapy Risk assessment Scale for high age patient).
  • Have Organized SABCS( San Antonio Breast Cancer update 2016 under the aegis of Delhi Breast Oncology Group.
  • Delhi Breast Oncology group meeting @ Manipal Hospital Dwarka in August 2018.
  • Co-Organizer of Best Of SABCS 2018 April 2018.
  • Organized workshop at Manipal Hospital Dwarka on Good Clinical Practice (GCP) on 1st March 2019.
  • CME on prostate cancer – CONFLUENCE meeting on Prostate Cancer -12 October 2019.
  • Dr. Peush Bajpai in an authored article on know the warning signs when to approach your doctor observing the Breast cancer Awareness month in the DNA. Click Here
  • Dr. Peush Bajpai explains about how early diagnosis and detection can identify Breast Cancer symptoms and treat it successfully on TV9 Bharatvarsh (Digital) | FB Live Session. Click Here
  • Dr. Peush Bajpai in an authored article on Watch out, lumps are not the only symptom of breast cancer observing Breast Cancer Awareness Month in Times Now News. Click Here
  • Dr. Peush Bajpai in an exclusive story on Oncologist answers FAQs on the ideal routine for cancer treatment in Times Now| World Cancer Day. Click Here
  • Dr. Peush Bajpai on Cancer and Precision Medicine in a live webinar on Business World.Click Here
  • Dr. Peush Bajpai on Cancer Treatment: Can I Have Chemotherapy During Pregnancy? in The Healthsite (Zee Digital) | Exclusive story.Click Here
  • Dr. Peush Bajpai on Doctor Explains: Menace of cancer in India| The Financial Express | World Cancer Day. Click Here
  • Dr. Peush Bajpai said in an exclusive Story, "Nearly 50-60 per cent cancers are due to poor lifestyle" to Financial Express. Click Here
  • SM Post | NDTV. Click Here
  • Overview

  • Dr. Peush Bajpai is a respected HOD and Consultant Medical Hemato-Oncologist at Manipal Hospitals, Delhi. With over 17 years of experience in the field, Dr. Bajpai has dedicated his career to the comprehensive treatment of various cancers, earning him a distinguished reputation among both patients and peers.

  • Moreover, Dr. Bajpai is equally well-versed with solid cancers like breast, lung, gastrointestinal, stomach, prostate, head, and neck as well as hematologic malignancies. Through his extensive experience, he is capable of offering individual and advanced cancer treatment according to each patient's needs.

  • Educationally, Dr. Bajpai completed his MBBS and MD in General Medicine before specialising with a DM in Medical Oncology from the Cancer Institute, Adyar, Chennai. He is also accredited by the European Society of Medical Oncology (ESMO), which underscores his commitment to maintaining the highest standards in oncology practice. His academic credentials are complemented by his participation in numerous research projects and clinical trials, which contribute to the advancement of cancer treatment and patient care.

  • Dr. Bajpai is actively involved in the broader medical community through his membership in several prestigious associations, including the Indian Medical Association (IMA), the Association of Physicians of India (API), and the Indian Society of Medical Oncology (ISMO). His involvement in these organizations reflects his dedication to staying at the forefront of medical advancements and best practices.

  • In addition to his clinical and academic work, Dr. Bajpai has contributed significantly to medical literature through numerous publications and presentations at national and international conferences. His research covers a wide range of topics within oncology, providing valuable insights and advancements that benefit both his patients and the broader medical community.

  • At Manipal Hospitals, Delhi, Dr. Bajpai, one of the best Oncologists in Delhi, leads a team of skilled professionals dedicated to delivering comprehensive and cutting-edge cancer care. His leadership and expertise ensure that patients receive the most effective treatments available, backed by the latest research and clinical guidelines.

  • Dr. Bajpai’s unwavering commitment as an Oncologist in Delhi, combined with his extensive experience and advanced skills, make him a trusted and valued figure in the field of oncology in Delhi. For patients seeking expert and compassionate cancer care, Dr. Peush Bajpai represents the epitome of professional excellence. Book your appointment today for optimum care and patient-centric support.

  • Fellowship & Membership

  • European Society of Medical Oncology (ESMO)
  • ASCO
  • NCR oncology group
  • ISMPO
  • ICON
  • Dwarka IMA
  • SIOP
  • Field of Expertise

  • Breast Cancer Management Gastrointestinal malignancies- Gastric, colo-rectal, hepatocellular carcinoma
  • Gynaecological Malignancies - Carcinoma Ovary, the endometrium
  • Haematological Malignancies - Multiple Myeloma, CML, CLL, and Autologous Bone marrow transplant
  • Soft-tissue Sarcomas and Osteosarcoma
  • Thoracic Malignancies - Lung Carcinoma
  • Immunotherapy
  • Precision Oncology
  • Languages Spoken

  • English
  • Hindi
  • Tamil
  • Awards & Achievements

  • First prize as a part of a team in a Case presentation at the UK Breast Oncoplasty Masterclass.
  • First prize in the All India Quiz at the Lymphoma leukemia meet in Mumbai organized by the European Society of Medical Oncology.
  • Best poster in BTG Hong Kong โ€Prospective evaluation of Musculoskeletal events in patients of CML on Imatinib Mesylate and correlation with electrolyte imbalances.

Doctor Videos

Blogs

Our Success Stories

Google Reviews

76 Google reviews

FAQ's

Patients often seek Dr. Peush Bajpai’s expertise as the HOD & Consultant - Medical Hemato Oncologist at Manipal Hospitals Dwarka - Delhi. Consult with Dr. Peush Bajpai one of the best Oncologist in Delhi. Visit our facility to meet our experts and to get their opinions.